THURSDAY, Aug. 22, 2024 (HealthDay News) -- Patients treated with neoadjuvant immune checkpoint inhibitor (ICI)-based therapy for hepatocellular carcinoma (HCC) have higher-risk disease features ...

Neoadjuvant therapy for high-risk renal cell carcinoma (RCC) may offer a survival advantage over adjuvant therapy, according to data presented at the 2024 annual meeting of the Society of Urologic ...

In this phase 3, open-label trial, we randomly assigned participants with locally advanced HNSCC in a 1:1 ratio to receive 2 cycles of neoadjuvant pembrolizumab and 15 cycles of adjuvant ...

The addition of immune checkpoint inhibitor therapy to neoadjuvant chemotherapy improved pathologic complete response and EFS for certain patients with early-stage breast cancer, according to a ...

Neoadjuvant HER2-targeted therapy, also known as preoperative treatment, is now the preferred approach for patients with locally advanced breast cancer (clinical stage IIB-IIIC according to American ...

The recommended dosage is 1500 mg of durvalumab every 3 weeks as neoadjuvant therapy and every 4 weeks as adjuvant therapy for patients with a body weight of 30 kg or more and 20 mg/kg for ...